TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06434584

Intervention type: OTHER
Intervention: with AI dosage assistance
Description: provide insulin dosage and confidence score with AI dosage assistance

Intervention type: OTHER
Intervention: with AI dosage assistance
Description: provide insulin dosage and confidence score with AI dosage assistance

Intervention type: OTHER
Intervention: with explainable AI assistance
Description: provide insulin dosage and confidence score with explainable AI assistance

Intervention type: OTHER
Intervention: with explainable AI assistance
Description: provide insulin dosage and confidence score with explainable AI assistance
Study: NCT02709031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cicletanine
Description: Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
Study: NCT06434584

Intervention type: OTHER
Intervention: with faulty explainable AI assistance
Description: provide insulin dosage and confidence score with faulty explainable AI assistance

Intervention type: OTHER
Intervention: with faulty explainable AI assistance
Description: provide insulin dosage and confidence score with faulty explainable AI assistance
Study: NCT06341946

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic third ventriculostomy
Description: role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
Study: NCT06550700

Intervention type: PROCEDURE
Intervention: laparoscopic hybrid surgery (LHS)
Description: First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
Study: NCT04704570

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Spinal stabilization exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Spinal stabilization exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Remotely and face to face evaluation of Functional Capacity Level
Description: Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.

Intervention type: OTHER
Group type: OTHER
Intervention: Remotely and face to face evaluation of Functional Capacity Level
Description: Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
Study: NCT05840679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation Solution
Description: Different concentrations of NaOCl are being used as the endodontic irrigant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation Solution
Description: Different concentrations of NaOCl are being used as the endodontic irrigant.
Study: NCT05896644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eat Well
Description: A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
Study: NCT05662904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
Description: CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
Study: NCT05787132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Board therapy
Description: Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perceptual Motor therapy
Description: Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
Study: NCT05826691

Intervention type: PROCEDURE
Intervention: Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).
Description: Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
Study: NCT03929289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Facilitation
Description: During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
Study: NCT04690192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNCT19
Description: 2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: 600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 105mg/m2, day -7 until -5,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Injection
Description: 60mg/m2, day -3, -2
Study: NCT04912323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold
Description: Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
Study: NCT06385548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
Study: NCT06023459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable extended-release buprenorphine
Description: Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual buprenorphine-naloxone
Description: Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
Study: NCT05970666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE with adebrelimab and bevacizumab
Description: TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
Study: NCT05517538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography-Needle Intramuscular Drug guidance
Description: EMG-guided needle neurotoxin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A injection into the Corrugator Supercilii muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A injection into the Corrugator Supercilii muscle
Study: NCT06177470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated deep iTBS
Description: Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Accelerated Sham iTBS
Description: Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
Study: NCT06198101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Technique
Description: The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique along with segmental vibrator
Description: this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
Study: NCT05639361

Intervention type: BEHAVIORAL
Intervention: Repeated Exposure
Description: Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.

Intervention type: BEHAVIORAL
Intervention: Repeated Exposure
Description: Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.

Intervention type: BEHAVIORAL
Intervention: Repeated Exposure
Description: Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
Study: NCT05358080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entelon Tab. 50mg
Description: twice daily for 24months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 24months
Study: NCT06173856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LED phototherapy
Description: LED phototherapy (430-470nm) alone will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Description: LED phototherapy (430-470nm) alone will be applied.
Study: NCT06171100

Intervention type: DRUG
Intervention: Tolvaptan
Description: Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group.

Intervention type: DRUG
Intervention: Tolvaptan
Description: Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group.
Study: NCT05460598

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: beddings with cooling effects
Description: beddings with cooling effects (mattress topper and bed linen)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: commonly used bedding
Description: commonly used bedding
Study: NCT06356779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local ablative therapy (LAT)
Description: Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
Study: NCT06149507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Prescribe the drug to the child

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Prescribe the drug to the child
Study: NCT04721275

Intervention type: OTHER
Intervention: measurement of pronostic sepsis scores
Description: qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).

Intervention type: OTHER
Intervention: measurement of pronostic sepsis scores
Description: qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
Study: NCT06239649

Intervention type: PROCEDURE
Intervention: Genicular nerve Radiofrequency Ablation block
Description: Genicular nerve Radiofrequency Ablation block
Study: NCT06072716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: chitosan loaded with miconazole nanoparticles gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: chitosan loaded with miconazole nanoparticles gel
Study: NCT05013567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen gel
Description: Ibuprofen gel 5% topically four times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel topically four times a day
Study: NCT05587400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: transfer a patient from semi-recumbent position to supine position with a 45° leg lifting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dobutamine test
Description: infusion dobutamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: nitric oxide inhalation
Study: NCT05766982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma will be applied to assess rate of wound healing.
Study: NCT05434013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarillo warnings-Surgeon General Text-Only
Description: Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarillo warnings-FDA proposed text-only
Description: Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarillo warnings-Pictorial
Description: Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
Study: NCT04808206

Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
Study: NCT06176495

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Educational Text Messages
Description: The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle.
Study: NCT06367907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: schema therapy
Description: In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: schema therapy
Description: In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
Study: NCT02850939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone app + patient navigation
Description: The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
Study: NCT06058338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce Prescription
Description: Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
Study: NCT05528900

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: allergy test
Description: allergy test are oral food challenge , prick test and IgE blood rate
Study: NCT04423458

Intervention type: DEVICE
Intervention: 3D imaging
Description: The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes.
Study: NCT04900610

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MenaQ7 ®, Nattopharma, ASA, Hovik, Norway
Description: daily per os supplementation of 1mg MK-7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MenaQ7 ®, Nattopharma, ASA, Hovik, Norway
Description: daily per os supplementation of 1mg MK-7
Study: NCT06414421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcuten Electriacal Nerve Stimulation
Description: In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
Study: NCT05788315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural Formulation Interview
Description: The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cultural Formulation Interview
Description: The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
Study: NCT04711941

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation training
Description: Rehabilitation with behavioural stimuli

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Description: Rehabilitation with behavioural stimuli
Study: NCT05325099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (subcutaneous injection) QOD x 3 times
Study: NCT06403410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delirium Prevention Guideline
Description: Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline is designed to be followed by nurses. However, collaboration with the physician is required for some aspects of the guideline (pain control, ordering/follow-up of laboratory tests, etc.). Support will be obtained from the intensive care physician, who is a member of the research team, for these steps. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00.
Study: NCT03775213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Tool with Active Monitoring
Description: The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Support Tool without Active Monitoring
Description: The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
Study: NCT06510829

Intervention type: DEVICE
Intervention: Diode laser
Description: Application of laser waves on the lesion